"A new microneedle patch being developed by the Georgia Institute of Technology and the Centers for Disease Control and Prevention (CDC) could make it easier to vaccinate people against measles and other vaccine-preventable diseases.
A demonstrated history of hypersensitivity to any component of the vaccine.
Infants who develop symptoms suggestive of hypersensitivity after receiving a dose of ROTARIX should not receive further doses of ROTARIX.
Gastrointestinal Tract Congenital Malformation
Infants with a history of uncorrected congenital malformation of the gastrointestinal tract (such as Meckel's diverticulum) that would predispose the infant for intussusception should not receive ROTARIX.
History Of Intussusception
Infants with a history of intussusception should not receive ROTARIX [see WARNINGS AND PRECAUTIONS]. In postmarketing experience, intussusception resulting in death following a second dose has been reported following a history of intussusception after the first dose [see ADVERSE REACTIONS].
Severe Combined Immunodeficiency Disease
Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive ROTARIX. Postmarketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered live, oral rotavirus vaccines and later identified as having SCID [see ADVERSE REACTIONS].
Last reviewed on RxList: 9/26/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Rotarix Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.